secwatch.observer — SEC 8-K summary
======================================

Issuer:     biote Corp. (BTMD)
CIK:        0001819253
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001193125-24-255973
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biote Q3 revenue $51.4M (+12.8% YoY); EPS $0.33; Adj. EBITDA $16.2M
-------------------------------------------------------------------

- Revenue of $51.4M, up 12.8% YoY; procedure revenue $37.9M.
- Gross profit margin 70.5%, up from 64.5% a year ago on vertical integration savings.
- Net income $12.7M ($0.33 diluted EPS) vs. $19.6M ($0.24) in Q3 2023.
- Adjusted EBITDA $16.2M, margin 31.5%; grew 15.4% YoY.
- Launched proprietary clinical decision support software in September 2024 to strengthen competitive position.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819253/000119312524255973/0001193125-24-255973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819253/000119312524255973/d880680d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-255973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer